TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Doctors leading this study hope to learn about the safety and effectiveness of combining
medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using
carboplatin and paclitaxel in the beginning of the study (induction) and if combining these
medications can increase tumor shrinkage after therapy and reduce the amount of radiotherapy
and chemotherapy that will later be needed.
In addition, the study is looking at ways to reduce side effects overall using robotic
surgery, chemotherapy and radiotherapy, or radiotherapy alone. Your participation in this
research will last about 2 years.
While HB-201 and HB-202 are FDA-approved for various conditions, the US Food and Drug
Administration (FDA) has not approved the combination of these drugs with chemotherapy for
the treatment of your condition, and therefore this can only be given in a research study.